In response to the acceleration of its preclinical and clinical research programs, Hemerion appointed Mélanie Rose to lead the innovation and expansion of its therapeutic solution pipeline based on Pentalafen® Heliance® technology.
Already in an advanced clinical stage for the treatment of glioblastoma, this therapeutic platform could quickly find new applications in oncology as a complement to surgery.
Mélanie Rose, a scientist in charge of part of Hemerion’s R&D programs since 2022, has been appointed Director of Scientific Innovation and Portfolio Expansion.
With a PhD in Oncology and Cancer Biology from the University of Lille, Mélanie Rose is a specialist in immuno-oncology and innovative treatments for brain tumors.
Her new role reflects the acceleration of Hemerion’s preclinical and clinical research programs dedicated to its therapeutic platform, which combines small molecules and dynamic phototherapy.
Rose’s mission is to expand the pipeline of clinical projects and evaluate the potential of Pentalafen®/Heliance® combination therapy for treating cancers after surgical resection.
While Hemerion’s therapy is at a very advanced and promising stage of clinical development for glioblastoma treatment, it could also improve the standard of care for many other oncology indications.
Rose also leads research programs combining Hemerion’s technology with immunotherapies for cancer treatment.